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Introduction
Ultrasound (US) guided core-needle biopsy of breast (CNB) is increasingly used for the diagnosis of breast lesions and is demonstrated to be highly sensitive and specific for the diagnosis of carcinomas. I ,2 It is also shown that immunostaining results for bcl-2, ER, c-erbB-2 and p53 on the CNB and the corresponding excision specimens are 100% concordant. 3
Her-2/nea (c-erb-B2) is an oncogene related to epidermal growth factor receptor family.4 It is overexpressed on a subset of in situ and invasive carcinomas of the breast. 5,6 In 90% of the cases Her-21nea protein overexpression is caused by gene amplification, and is shown to be independently associated with poor prognosis in women with 8 - 15 However discordance between expression and genomic amplification occurs in about 3 to 15% of cases. 9 ,13,16 The clinical significance of lower levels of immunoexpression (2) and such discordance between genomic amplification and oncoprotein expression still remains uncertain. 9 ,12,13,16 The aim of this study was (i) to search the concordance between genomic amplification and oncoprotein expression of Her-2/nea (ii) to evaluate the correlation between Her-2/nea and status with other prognostic factors such as histologic grade, tumor stage, lympho/vascular invasion, surgical margin status and Paget's disease.
Materials and Methods
We studied 15 patients who had a US guided breast CNB with a diagnosis of infiltrative ductal carcinoma followed by mastectomy and axilla dissection. The median time to radical mastectomy was 21 days (range, 7-42 days). Patients received no radiation therapy or chemotherapy between the US guided CNB and the radical mastectomy. CNB was performed free hand with a 14 gauge needle biopsy gun (Magnum Bard Covington Ga) under US guidance. FISH and immunohistochemistry techniques were applied to CNB specimens. Clinical data was collected from patient records, tumors were staged according to TNM (1999) classification and histological grading was done according to World Health Organizations reccomendations. Complete data is presented in Table 1 .
DNA Probes
The following fluorophore-labeled locus specific identifier (LSI) DNA probes were used: LSI HER-2/neu DNA Spectrum Orange/ CEP17 Spectrum Green (Vysis), LSIIWCP hybridization (Dextran sulphate, formamide, SSC).
Fluorescence in situ hybridization
We performed fluorescence in situ hybridization analysis on 5 ]Jm serial sections of the selected cases. Sections were dewaxed in xylene (2X5 min), rinsed in 100% ethanol (2X5 min) and air-dried. Prior to FISH, the slides were placed in a plastic Coplin jar filled with PBS for 5 minutes and dehydrated in ethanols (70%, 80%, and 90%). After air drying, sections were pre-treated by 2X standard saline citrate (SSC) for 30 min at 3rC, followed by 0.01 NHCL 100 ]Jl pepsin treatment for 10 min at 3rC. 2X SSC treatment was applied at room temperature for 5 min. Then sections were placed in a plastic Coplin jar filled with denaturation solution (70% formamide/2X SSC) at 73°C for 5 min, followed by dehydration in ethanol (70%, 80%, 90%). The prewarmed probe was applied to the target area on slides followed by placement in a prewarmed humidified chamber in a 3rC incubator for 12 hours. After hybridization, the slides were washed in O.4X SSC/0.3% NP-40 mixture for 2 minutes and then in O.4X SSC/O.1 % NP-40 at 73°C for 2 seconds. The slides were counterstained with 4,6-diamindino-2-phenylindole (DAPI) and a coverslip was applied.
Evaluation
An Olympus BX 40 fluorescence microscope was used for scoring signal copy numbers from a minimum of 40 nuclei per hybridization for each probe from the previously mapped carcinomatous foci. One pattern consisted of two orange and two green signals, reflecting a normal disomic complement for both HER-2/neu and centromere 17. HER-2/neu gene copy amplification was classified as absent (one to four gene copies), borderline (four to eight gene copies), or positive/present (more 
Immunohistochemistry
Immunohistochemistry was performed on the serial sections of the cases. 5 11m sections were deparaffinized in xylene, and rehydrated in descending grades (100%-70%) of ethanol. Deparaffinized slides were placed on the Ventana ES automated immunostainer and stained with the following protocol: c-erbB-2 monoclonal antibody (BioGenex CB11) for 30 min. The staining was completed with the 3-amino-3-ethylcarbazole (AEC) detection kit, and slides were counterstained with Mayer hematoxylin. Enzyme digestion was not used. Similar sections were also stained HER2/neu according to the instructions of the manufacturer and using the reagents included in the HercepTest kit. The primary antibody included in the kit was polyclonal in a prediluted form. A known HER2/neu positive case of ductal carcinoma was used as the positive immunostaining control and two antibodies were used as a negative control. Tissue was processed in the same way except that the primary antibody was omitted.
Interpretation
Without knowledge of the results of the FISH tests and following the criteria recommended by DAKO for the HercepTest all slides were reviewed by two pathologists, Overexpression of HER2/neu was defined as membranous staining in more than10% of the neoplastic cells. Partial or PATHOLOGY ONCOLOGY RESEARCH Her-2 /neu Gene Amplification and Protein Expression incomplete, weak to moderate, and moderate to strong membraneous staining in more than 10% of the tumor cells were scored as 1 (negative), 2 (weak positive) and 3 (strong positive), respectively. The consensus was viewed as conclusive for indeterminate cases.
Statistical Analysis
Statistical analysis was based on two-sided Chi-Square test. The computations were performed using GraphPad InStat version 2.04 (GraphPad software USA). The satistical difference was considered significant if the p value was less than 0.05.
Results
The age of the patients at diagnosis ranged from 36 to 79 years (median, 60). Nine of the cases were stage T1, five of the cases were stage T2, one of the cases was T3. Histological Grading was performed by Scarff-Bloom-Richardson System and two cases were grade 1, one case was grade 3, the rest of all (12 cases) were grade 2.Two (2/15) of the Table 1) .
Direct 2-colour Her-2/neu chromosome 17 FISH analysis was performed on 15 cases. The use of chromosome 17 has important means in correcting Her-2/neu pseudoamplification due to chromosome 17 polysomy and the presence of the chromosome 17 probe also serves as an additional positive control for hybridization reaction.
Amplification was demonstrated in 27% (4/15) of the cases (Figure 1,2,3) . The Her-2/neu-CEP17 ratio ranged from 2.1 to 11.7 (median 8.3)
Her-2/neu protein overexpression was detected in 47% (7/15), and 80% (12/15) of the cases with CBlland the HercepTest respectively (Table 1, Figure 4 ). Four cases that showed amplification of the Her-2/neu gene, demonstrated strong 3x immunostaining with HercepTest and all of these cases demonstrated either weak 2x or negative Ix immunohistochemical staining with CB 11. From four amplified cases, one had lymph node metastasis and two other cases showed lympho/vascular invasion. We revealed statistically significant correlation between the oncogene amplification and oncoprotein overexpression (p<0.05), except for insignificant correlation between the HercepTest and CB11 overexpression. Statistically we found a significant correlation between the tumor stage and grade (p<0.05), but was not revealed correlation between oncoprotein expression or gene amplification (p<0.05).
Discussion
The Her-2/neu gene encodes a transmembrane protein with an extracellular growth factor receptor domain and an intracellular kinase domain. I8 Although some studies showed that genomic amplification of the Her-2/neu gene in patients with invasive breast carcinoma has been associated with a significant reduction in metastasis-free survival, other studies failed to confirm these findings.? The discordant findings in many of these studies might be related to technical variables associated with the methodologies used for detection of gene amplification or overexpression. Immunohistochemistry performance with different methods varies widely because of dilution artefacts by solid matrix blotting, antigenic alterations due to tissue fixation and extreme variability in the sensitivity of the available anti-erbB-2/ Her-2 antibodies. 19, 20 Sequence complementary DNA probes are used in FISH technique to quantify cellular Her-2/neu gene copy number and Her-2/neu gene copies relative to chromosome 17 number distinguishes the gene amplification from chromosomal aneuploidy.9 FISH is a more objective and quantitative method compared to immunohistochemistry but FISH technique can also be complicated by nuclear truncation, which obscures enumeration of signals.
In this study we revealed a statistically significant association between gene amplification and protein overexpression with a concordance rate of 100 % for HercepTest and CB 11. The cases which demonstrated gene amplification showed strong 3x overexpression with HercepTest or weak 2x and negative Ix immunostaining with CB11. This finding has concordance with the studies, which suggest that weak 2x overexpression is not specific to gene amplification. 8 ,12,21 The clinical significance of lower levels of immunoexpression 2x and such discordance between genomic amplification and oncoprotein expression still remains uncertain. 9 ,12,13,16 on our study, among cases demonstrating weak 2x or negative with Ix protein expression, no gene amplification was detected in 8 of 12 cases with Hercept Test and BioGenex antibodies in 3 of 7 cases was not detected. Even one case that had strong 3x immunostaining with HercepTest did not demonstrate gene amplification. True overexpression without gene amplification has been described in 3 to 10% of breast carcinomas. 13 ,16 It is unclear whether they represent highly sensitive staining or a subset of cases that show overexpression without amplification. Ratcliffe et al,13 demonstrated that amplification of the gene is an early event that might in some cases precede overexpression of the protein. 13 On the other hand, Tubbs et a1,21 demonstrated that discrepancies are not due to transcriptional regulation with overstatement of mRNA and Her-2/neu oncoprotein in the absence of genomic amplification, but rather false positive immunohistochemistry results. 21 In our study antibodies in oncoprotein overexpression demonstrated a statistically insignificant association. Five cases, which showed Her-2/neu oncoprotein overexpression with HercepTest, did not demonstrate immunoexpression with CB 11.
In this study IHC and FISH methods display concordances but weak 2x immunoexpression results with HercepTest should be interpreted with caution in evaluating the results of IHC. We believe that combination of IHC and FISH methods enhances the evaluation of tumor genetics at both gene and protein level for the analysis of Her-2/neu in breast carcinoma.
